Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Botulinum neurotoxins: A distinct subclass of SNARE-Cleaving endopeptidases.

Anaerobe·2026
Same author

Iatrogenic botulism: a risk for botulinum toxin's medical use?

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Identification and characterization of botulinum neurotoxin-like two-component toxins in <i>Paeniclostridium ghonii</i>.

Science advances·2025
Same author

Botulinum neurotoxin Light Chain/A1 uses fast synaptic vesicle cycling to cleave plasma membrane bound SNAP-25.

Communications biology·2025
Same author

Bifunctional Inhibition of Botulinum Neurotoxin A Protease: Unexpected Active Site Inhibition Enhances Covalent Targeting of an Allosteric Site.

Journal of medicinal chemistry·2025
Same author

Expression of Recombinant Clostridial Neurotoxin by <i>C. tetani</i>.

Microorganisms·2025

Related Experiment Video

Updated: May 16, 2026

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

Progress in cell based assays for botulinum neurotoxin detection.

Sabine Pellett1

  • 1Department of Bacteriology, University of Wisconsin, Madison, WI 53706, USA. sludwig@wisc.edu

Current Topics in Microbiology and Immunology
|December 15, 2012
PubMed
Summary

Botulinum neurotoxins (BoNTs), potent toxins used as pharmaceuticals, can now be quantified using advanced cell-based assays. These in vitro methods offer a reliable alternative to traditional mouse bioassays for BoNT potency determination.

More Related Videos

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

Related Experiment Videos

Last Updated: May 16, 2026

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

Area of Science:

  • Biochemistry
  • Toxicology
  • Pharmacology

Background:

  • Botulinum neurotoxins (BoNTs) are highly potent toxins and essential pharmaceuticals, but their accurate potency determination is critical.
  • BoNTs are modular proteins that exert toxicity through a multi-step cellular intoxication process.
  • Current methods for BoNT potency assessment face challenges related to cost, ethics, and comprehensive evaluation of functionality.

Purpose of the Study:

  • To evaluate the efficacy of cell-based assays as alternatives to traditional in vivo mouse bioassays for determining the potency of Botulinum neurotoxins (BoNTs).
  • To highlight the advancements in in vitro methods for quantitative BoNT potency determination, crucial for pharmaceutical development and research.

Main Methods:

  • Review of existing literature on Botulinum neurotoxin (BoNT) assays.
  • Comparison of cell-based assay performance against the established in vivo mouse bioassay.
  • Analysis of the multi-step intoxication pathway of BoNTs and its relevance to assay design.

Main Results:

  • Cell-based assays have emerged as a viable in vitro alternative for quantifying fully functional BoNTs.
  • Recent cell-based assays demonstrate comparable or superior sensitivity to the mouse bioassay for BoNT potency determination.
  • These assays provide a comprehensive assessment of BoNT activity, encompassing all intoxication pathway steps.

Conclusions:

  • Cell-based assays represent a significant advancement for the reliable and quantitative potency determination of Botulinum neurotoxins (BoNTs).
  • These in vitro methods address the ethical and cost concerns associated with traditional mouse bioassays.
  • The development of robust cell-based assays is vital for pharmaceutical BoNT development, basic research, and antibody detection.